A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children.

A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children.

Brousseau D (2015) Blood  (Link to Abstract)           

Multicentre, randomized, parallel, double blind, placebo-controlled trial comparing: intravenous Magnesium 40 mg/Kg q8 hourly versus normal saline plus standard therapy for the treatment of pain crisis for patients with Sickle cell anemia. Hypothesis it would reduce length of stay (LoS), opioid use and improve QoL.

204 children eligible: n=101 magnesium and n=103 placebo. The addition of intravenous magnesium did not shorten length of stay, reduce opioid use, or improve quality of life in children hospitalized for sickle cell pain crisis.

* IV Magnesium doesn’t help children with SCD pain crisis.

Joomla! Debug Console

Session

Profile Information

Memory Usage

Database Queries